Clinical efficacy of immunotherapy plus target therapy for preventing postoperative recurr-ence of hepatocellular carcinoma after associating liver partition and portal vein ligation for staged hepatectomy
10.3760/cma.j.cn115610-20221123-00708
- VernacularTitle:免疫联合靶向治疗预防肝细胞癌行ALPPS术后复发的临床疗效
- Author:
Minjie SHANG
1
;
Jungang ZHANG
;
Zongting GU
;
Fangqiang WEI
;
Ran TAO
;
Guoqing WU
;
Yang WEN
;
Jian SHEN
;
Yuqi TANG
Author Information
1. 浙江省人民医院肝胆胰腺外科 微创外科，杭州 310014
- Keywords:
Liver neoplasms;
Residual liver volume;
Two-step hepatotomy;
Tumor recurrence;
Targeted therapy;
Immunotherapy;
Prognosis
- From:
Chinese Journal of Digestive Surgery
2023;22(2):281-285
- CountryChina
- Language:Chinese
-
Abstract:
Surgical resection in patients with advanced primary carcinoma of liver has high risks of early recurrence and incidence of portal vein tumor thrombus, caused by insufficient resi-dual liver volume after two-steps hepatotomy. At present, the treatment for patients with advanced primary carcinoma of liver is limited, thus can't satisfy the requirement of patient for treatment. The authors introduce the clinical experience of a patient with hepatocellular carcinoma and insufficient residual liver volume who underwent preventive immunotherapy plus target therapy after associa-ting liver partition and portal vein ligation for staged hepatectomy, in order to provide reference for relevant treatment.
